ESA 4 - CPT all qs Flashcards
Question 1
A 57 year old man attends a hypertensive clinic after having his blood pressure measured at his local pharmacy during their hypertension awareness program. His blood pressure is confirmed to be 155/100 at the clinic. He reports no other significant medical history.
a) What classification would you assign this blood pressure based on the joint BHS/NICE guidelines? (1 mark)
155/100 mmHg = STAGE 2
Case 1
A 57 year old man attends a hypertensive clinic after having his blood pressure measured at his local pharmacy during their hypertension awareness program. His blood pressure is confirmed to be 155/100 at the clinic. He reports no other significant medical history.
b) With the information that you have, what class of antihypertensive would you suggest for this patient and suggest an appropriate drug. (2 marks)
Calcium Channel Blocker (Dihydropyridine) (1 mark)
(1 Mark for any one of the following or others in the class) Amlodipine Nifedipine Nicardipine
NOT verapamil or diltiazem
Case 1
A 57 year old man attends a hypertensive clinic after having his blood pressure measured at his local pharmacy during their hypertension awareness program. His blood pressure is confirmed to be 155/100 at the clinic. He reports no other significant medical history.
c) ACE Inhibitors can reduce hypertension. (i) Name the conversion step at which these drugs act (ii) Name two actions of ACE inhibitors that contribute to lowering blood pressure. (2 marks)
i) At the point of converting Angiotensin 1 to Angiotensin II by ACE (1 mark)
1/2 mark each for any two of the following:
ii) Reduced vasoconstriction Reduced sympathetic activity
Reduced aldosterone release leading to reduced salt and water retention
Case 1
A 57 year old man attends a hypertensive clinic after having his blood pressure measured at his local pharmacy during their hypertension awareness program. His blood pressure is confirmed to be 155/100 at the clinic. He reports no other significant medical history.
d) State two ADRs that you would discuss with a patient when prescribing an ACE inhibitor. (2 marks)
Award 1 mark for any of the following – max two marks: Dry cough (10-15%) Angioedema uncommon but more prevalent in African Caribbean populations Renal failure (incl. renal artery stenosis) Hyperkalaemia
Case 1
A 57 year old man attends a hypertensive clinic after having his blood pressure measured at his local pharmacy during their hypertension awareness program. His blood pressure is confirmed to be 155/100 at the clinic. He reports no other significant medical history.
e) In patients with resistant hypertension, who have been prescribed drugs in accordance with guidelines up to and including step three, additional add on drugs can be prescribed. Name ONE class of drug that may be considered, provide an example from this class and briefly describe how it lowers blood pressure. (3 marks)
Spironolactone is a mineralocorticoid receptor antagonist. Prevents aldosterone action (reduction of blood volume) OR
Alpha blocker cause vasodilation reducing the pressure at which blood is ejected into vasculature OR
Beta blocker – beta adrenergic receptor antagonist, lower renin levels, negative chronotropic and inotropic effects, decreased cardiac output
Question 2
A 42 year old female has recently been diagnosed with type II diabetes. She is attending the GP for a medication review.
a) What clinical marker will the GP measure to access how well her diabetes is being controlled and what target (%) would they be hoping for? (2 marks)
HbA1c (1 mark) 6.5% in first two treatment steps (1 mark)
Question 2
A 42 year old female has recently been diagnosed with type II diabetes. She is attending the GP for a medication review.
b) She is currently taking metformin TDS. How does metformin help control her diabetes? (3 marks)
Decrease insulin resistance (sensitivity of own insulin), (1 mark) increasing glucose uptake and utilisation in target tissues (skeletal muscle) (1 mark). Reduces hepatic glucose production. (Limits weight gain) (1 mark).
Question 2
A 42 year old female has recently been diagnosed with type II diabetes. She is attending the GP for a medication review.
c) What non-pharmacological intervention would be recommended upon diagnosing type II diabetes? What considerations should be discussed with patients when initiating therapy which are often related to poor adherence? (3 marks)
Non-pharmacological intervention (1 mark)
Managed weight reduction (1 mark)
Considerations to be discussed (2 marks)
Increased risk of weight gain (1 mark) Hypoglycaemia (1 mark)
Question 2
A 42 year old female has recently been diagnosed with type II diabetes. She is attending the GP for a medication review.
d) People with type II diabetes are at greater risk of suffering from atrial fibrillation. Which class of drug would you recommend for rate control in atrial fibrillation? Which drug would you prescribe? (2 marks)
Beta blocker (1 mark) – bisoprolol (1 mark)
OR
Calcium channel blocker (1 mark) – either verapamil (1 mark)
OR
diltiazem (1 mark)
Question 3
You are the Lead Clinician in a clinical trial for a new chemotherapeutic drug, BAY 28672. You are responsible for overseeing analysis of the pharmacokinetic properties of the drug in a Phase 0 trial.
a) Initial results show that the oral bioavailability of the drug is 0.2. If the total amount of BAY 28672 given orally was 70 mg, what amount of the drug would be available to afford a therapeutic effect? (1 mark)
We are told F (oral bioavailability) = 0.2 So if the total amount given was 70 mg and the oral bioavailability was 0.2 then 0.2 x 70 mg = 14mg (1 mark)
Question 3
You are the Lead Clinician in a clinical trial for a new chemotherapeutic drug, BAY 28672. You are responsible for overseeing analysis of the pharmacokinetic properties of the drug in a Phase 0 trial.
b) The low oral bioavailability means the i.v. route is preferred for administration. A plot of its pharmacokinetic profile is shown below. By using the graph below estimate the half-life of the drug.
Pharmacokinetics following single iv administration
x-axis: Time in Hours 0 10 20 30 40 50 60 70 80 90 100
y-axis: Plasma Concn (mg/L) 0 2.5 5 7.5 10 12.5
(1 mark)
20 hrs (1 mark)
Question 3
You are the Lead Clinician in a clinical trial for a new chemotherapeutic drug, BAY 28672. You are responsible for overseeing analysis of the pharmacokinetic properties of the drug in a Phase 0 trial.
c) Results from the study revealed that BAY 28672 had a clearance rate of 5ml/kg/hr. With this information calculate the apparent volume of distribution.
The equation: t1/2 = 0.693 x Vd/CL should help you. (3 marks)
Step 1. 20 hrs = 0.7 x Vd/5ml/kg/hr
Step 2. 20 hrs x 5 ml/kg/hr = 0.7 xVd = 100 ml/kg (the hours cancel)
Step 3. 100 ml/kg/0.7 = Vd = 142 ml/kg
(1 mark for each step)
Question 3
You are the Lead Clinician in a clinical trial for a new chemotherapeutic drug, BAY 28672. You are responsible for overseeing analysis of the pharmacokinetic properties of the drug in a Phase 0 trial.
d) The volume of distribution of a modified preparation is calculated and reported to be significantly higher than the previous drug. How would you expect the t ½ to compare to the old drug? (1 mark)
Increase. Vd is proportional to t1/2 (1 mark)
Question 3
You are the Lead Clinician in a clinical trial for a new chemotherapeutic drug, BAY 28672. You are responsible for overseeing analysis of the pharmacokinetic properties of the drug in a Phase 0 trial.
e) One of the participants in the phase 0 trial, develops breast cancer aged 55 (unrelated to the trial). Name the type of hormone replacement therapy (HRT) that increase the risk of breast cancer. Provide an example drug from this class. (2 marks)
Opposed oestrogen therapy (1 mark)
Estradiol with medroxyprogesterone, levonorgestrel or dydrogesterone. Many other combinations but above are commonly used. Specific dose combinations and trade names do not need to be learnt.
Longer term unopposed HRT can increase risk of breast cancer and is suggested to be associated with increased age and other risk factors.
Question 3
You are the Lead Clinician in a clinical trial for a new chemotherapeutic drug, BAY 28672. You are responsible for overseeing analysis of the pharmacokinetic properties of the drug in a Phase 0 trial.
f) Tamoxifen is discussed as an appropriate chemotherapeutic agent. What does this information suggest about the breast cancer diagnosis and to what class of chemotherapies does it belong? (2 marks)
Oestrogen receptor positive (1 mark) SERM (1 mark)